ENTRY       D04023                      Drug
NAME        Erlotinib hydrochloride (JAN/USAN);
            Tarceva (TN)
PRODUCT     TARCEVA (Genentech)
  GENERIC   ERLOTINIB (Areva Pharmaceuticals)
            ERLOTINIB (Armas Pharmaceuticals)
            ERLOTINIB (Armas Pharmaceuticals)
            ERLOTINIB (Armas Pharmaceuticals)
            ERLOTINIB (Aurobindo Pharma Limited)
            ERLOTINIB (Breckenridge Pharmaceutical)
            ERLOTINIB (Cadila Healthcare Limited)
            ERLOTINIB (Sun Pharmaceutical Industries)
            ERLOTINIB (Teva Pharmaceuticals USA)
            ERLOTINIB (Zydus Pharmaceuticals USA)
            ERLOTINIB HYDROCHLORIDE (Alembic Pharmaceuticals Limited)
            ERLOTINIB HYDROCHLORIDE (Alembic Pharmaceuticals)
            ERLOTINIB HYDROCHLORIDE (MSN LABORATORIES PRIVATE LIMITED)
            ERLOTINIB HYDROCHLORIDE (Novadoz Pharmaceuticals LLC)
FORMULA     C22H23N3O4. HCl
EXACT_MASS  429.1455
MOL_WEIGHT  429.8967
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03162  EGFR inhibitor
            Metabolizing enzyme substrate
             DG01892  CYP1A2 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 4291
            ATC code: L01EB02
            Chemical structure group: DG00711
            Product (DG00711): D04023<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
  DISEASE   Non-small cell lung cancer (EGFR mutation positive) [DS:H00014]
            Pancreatic cancer [DS:H00019]
TARGET      EGFR* [HSA_VAR:1956v2] [HSA:1956] [KO:K04361]
  PATHWAY   hsa04010(1956)  MAPK signaling pathway
            hsa04012(1956)  ErbB signaling pathway
            hsa05200(1956)  Pathways in cancer
            hsa05212(1956)  Pancreatic cancer
            hsa05223(1956)  Non-small cell lung cancer
METABOLISM  Enzyme: CYP3A4 [HSA:1576], CYP1A2 [HSA:1544]
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
                 L01EB02 Erlotinib
                  D04023  Erlotinib hydrochloride (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Erlotinib
                D04023  Erlotinib hydrochloride (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D04023  Erlotinib hydrochloride (JAN/USAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03162  EGFR inhibitor
                 DG00711  Erlotinib
                  D04023  Erlotinib hydrochloride
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               DG00711  Erlotinib
                D04023  Erlotinib hydrochloride
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00711  Erlotinib
                 D04023  Erlotinib hydrochloride
            Drug classes [BR:br08332]
             Antineoplastic
              DG03162  EGFR inhibitor
               D04023  Erlotinib hydrochloride
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                EGFR* [HSA_VAR:1956v2]
                 D04023  Erlotinib hydrochloride (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D04023
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D04023
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D04023
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D04023
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D04023
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D04023
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03162  EGFR inhibitor
                 DG00711  Erlotinib
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               DG00711  Erlotinib
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00711  Erlotinib
DBLINKS     CAS: 183319-69-9
            PubChem: 17398007
            ChEBI: 53509
            LigandBox: D04023
ATOM        30
            1   C8x C    10.3936  -13.0286
            2   N5x N    10.3936  -14.4351
            3   C8y C    11.6594  -15.1383
            4   C8y C    12.8550  -14.4351
            5   C8y C    12.8550  -13.0286
            6   N5x N    11.6594  -12.3253
            7   C8x C    14.0505  -15.1383
            8   C8y C    15.2460  -14.4351
            9   C8y C    15.2460  -13.0286
            10  C8x C    14.0505  -12.3253
            11  N1b N    11.6594  -16.4745
            12  C8y C    12.8550  -17.1777
            13  C8x C    12.8550  -18.5842
            14  C8y C    14.0505  -19.2875
            15  C8x C    15.2460  -18.5842
            16  C8x C    15.2460  -17.1777
            17  C8x C    14.0505  -16.4745
            18  O2a O    16.4640  -12.3253
            19  C1b C    17.6821  -13.0286
            20  C1b C    18.9002  -12.3253
            21  O2a O    20.1182  -13.0286
            22  C1a C    21.3363  -12.3253
            23  O2a O    16.4640  -15.1383
            24  C1b C    17.6821  -14.4351
            25  C1b C    18.9002  -15.1383
            26  O2a O    20.1182  -14.4351
            27  C1a C    21.3363  -15.1383
            28  C3b C    14.0500  -20.7199
            29  C3a C    14.0500  -22.1199
            30  X   Cl   26.8496  -15.6306
BOND        31
            1     1   2 1
            2     2   3 2
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 2
            7     4   7 2
            8     7   8 1
            9     8   9 2
            10    9  10 1
            11    5  10 2
            12    3  11 1
            13   11  12 1
            14   12  13 2
            15   13  14 1
            16   14  15 2
            17   15  16 1
            18   16  17 2
            19   12  17 1
            20    9  18 1
            21   18  19 1
            22   19  20 1
            23   20  21 1
            24   21  22 1
            25    8  23 1
            26   23  24 1
            27   24  25 1
            28   25  26 1
            29   26  27 1
            30   14  28 1
            31   28  29 3
///
